Rapport Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-56.6M | $-19.9M | $-33.8M | $-26.9M | $-26.7M | $-24.1M | $-20.0M | $-17.5M |
| Depreciation & Amortization | $212.0K | $227.0K | $265.0K | $256.0K | $252.0K | $244.0K | $260.0K | $219.0K |
| Depreciation | $200.0K | $200.0K | $200.0K | $300.0K | $300.0K | $200.0K | $200.0K | $200.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $7.2M | $7.0M | $5.7M | $4.7M | $4.4M | $4.0M | $3.2M | $3.2M |
| Net Cash from Operating Activities | $-41.5M | $-13.1M | $-24.7M | $-17.5M | $-25.1M | $-20.2M | $-14.4M | $-16.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $78.0K | $86.0K | $169.0K | $134.0K | $22.0K | $291.0K | $226.0K | $140.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $25.6M | $37.9M | $-174.3M | $-56.8M | $22.6M | $21.0M | $31.9M | $-53.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.4M | $531.0K | $311.0K | $270.5M | $-63.0K | $5.0K | $7.0K | $-1.4M |
| Net Change in Cash | $-14.4M | $25.4M | $-198.7M | $196.3M | $-2.5M | $799.0K | $17.5M | $-70.9M |
| Free Cash Flow | $-41.5M | $-13.1M | $-24.9M | $-17.6M | $-25.1M | $-20.5M | $-14.7M | $-16.6M |